Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 590

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 590
---
                       ​ 
 Year Ended December 31, | ​ | ​    
 2022 |       ​ 
       ​ |
|:----------------------------------------------------|:--|:------------------|--------------:|:--|:-----|--------:|:--|:-----|------------------------:|:--|:-----|--------:|
| Net cash used in operating activities               | ​ | $                 |       -13,472 | ​ | $    | -15,291 | ​ | $    |                 -21,040 | ​ | $    | -17,866 |
| Net cash provided by (used in) investing activities | ​ |                   |             — | ​ |      |  22,468 | ​ |      |                  22,468 | ​ |      | -22,000 |
| Net cash (used in) provided by financing activities | ​ |                   |            -9 | ​ |      |       2 | ​ |      |                       2 | ​ |      |       4 |
| Net (decrease) increase in cash                     | ​ | $                 |       -13,481 | ​ | $    |   7,179 | ​ | $    |                   1,430 | ​ | $    | -39,862 |

Operating Activities Net cash used in operating activities was $13.5 million for the nine months ended September 30, 2024, reflecting a net loss of $16.7 million and net changes in operating assets and liabilities of $2.8 million, partially offset by non-cash charges for depreciation

323

and amortization, stock-based compensation expense, and non-cash lease expense of $0.4 million. The net changes in operating assets and liabilities of $2.8 million was primarily driven by (i) a $2.0 million decrease in prepaid expenses and other current assets, attributable to the timing of patient enrollments, and (ii) a $0.9 million increase in accounts payable and accrued expenses, driven by the timing of invoices and payments.

Net cash used in operating activities was $15.3 million for the nine months ended September 30, 2023, reflecting a net loss of $13.0 million and net changes in operating assets and liabilities of $2.4 million, partially offset by non-cash charges for depreciation and amortization, stock-based compensation expense, non-cash lease expense and accretion of discounts on short-term investments of $0.1 million.